Efficacy of Lecanemab in patients with Parkinson's disease with a positive amyloid PET scan

Efficacy of Lecanemab in patients with Parkinson's disease with coexistent Alzheimer's disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0011866

Enrollment

Registered

2026-04-17

Start date

2026-04-30

Completion date

Unknown

Last updated

2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : This study plans to consecutively enroll the patients with Parkinson's disease (PD) who have confirmed amyloid deposition on amyloid imaging and meet the indications for lecanemab administratio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with Parkinson's disease 2. Amyloid deposition confirmed by Florbetaben positron emission tomography 3. Mild cognitive impairment or early dementia (Clinical Dementia Rating : 0.5 or 1) on neuropsychological tests 4. Adults aged 50-90 years

Exclusion criteria

Exclusion criteria: 1. Cases in which lecanemab administration is contraindicated (based on recommendations from the Korean Dementia Association) 2. Cases in which neuropathologies other than Parkinson's disease or Alzheimer's disease are suspected as the underlying disease

Design outcomes

Primary

Measure	Time frame
Changes in amyloid dposition on amyloid imaging scans after 18 months of lecanemab administration in the lecanemab adminstration group	—

Secondary

Measure	Time frame
Longitudinal changes in cognitive function;Longitudinal changes in parkinsonian motor deficits;Longitudinal changes in the plasma and cerebrospinal fluid biomarkers in the lecanemab administration group	—

Countries

Korea, Republic of

Contacts

Public ContactSeok Jong Chung

Yonsei University Health System, Severance Hospital

sjchung@yuhs.ac+82-2-2228-1602

Outcome results